A phase 1 study of MDM2 inhibitor DS-3032b in patients with well/de-differentiated liposarcoma (WD/DD LPS), solid tumors (ST) and lymphomas (L).-Reference-Cited by-同舟云学术

A phase 1 study of MDM2 inhibitor DS-3032b in patients with well/de-differentiated liposarcoma (WD/DD LPS), solid tumors (ST) and lymphomas (L).

Published:2018-05-20 Issue:15_suppl Volume:36 Page:11514-11514
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Bauer Todd Michael¹,Gounder Mrinal M.²,Weise Amy M.³,Schwartz Gary K.⁴,Carvajal Richard D.⁴,Kumar Prasanna⁵,Zernovak Oleg⁶,Beck Alida⁷,Doyle Jana⁸,Mendell-Harary Jeanne⁹,Kochan Jarema Peter¹⁰,Chen Shuquan¹¹,LoRusso Patricia¹²,Tap William D.¹³,Somaiah Neeta¹⁴,Hyman David Michael¹⁵,Meric-Bernstam Funda¹⁶,Hong David S.¹⁷

Affiliation:

1. Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN;

2. Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY;

3. Karmanos Cancer Institute, Detroit, MI;

4. Columbia University Medical Center, New York, NY;

5. Daiichi Sankyo Co., Ltd., Collegeville, PA;

6. Daiichi Sankyo, Inc, Edison, NJ;

7. Memorial Sloan Kettering Cancer Center, New York, NY, US;

8. Daiichi Sankyo Incorporated, Edison, NJ;

9. Daiichi Sankyo, Edison, NJ;

10. Daiichi Sankyo Pharma Dev, Edison, NJ;

11. Daiichi Sankyo Inc., Basking Ridge, NJ;